More Wuhan YZY Biopharma Co., Ltd. news
Wuhan YZY Biopharma Co., Ltd.HKEX: 2496

Documents on Display

Oct 30, 2026 at 7:09 AM EDT · Issued by Wuhan YZY Biopharma Co., Ltd. via HKEXnews

Filed with HKEX · Stock code 2496 · Oct 30, 2026 at 7:09 AM EDT

On 6ix: 6ix.com/news/documents-on-display-84

View Attachment

6ix is reading this filing.

View original source (HKEXnews)Wuhan YZY Biopharma Co., Ltd. on 6ix

Earlier from Wuhan YZY Biopharma

  • Form of proxy for the extraordinary general meeting to be held on Tuesday, 17 November 2026Oct 30
  • Notice of extraordinary general meetingOct 30
  • (1) Connected transaction in respect of the proposed issue of new domestic shares under specific mandate; (2) application for whitewash waiver; (3) proposed amendments to the articles of association; and (4) notice of egmOct 30
  • Closure of register of members for extraordinary general meetingOct 28
  • Voluntary announcement the first patient dosed in phase i clinical trial of Y225 for treatment of hemophilia aOct 16

Later from Wuhan YZY Biopharma

  • Announcement despatch of circular in relation to (1) connected transaction in respect of the proposed issue of new domestic shares under Specific mandate; (2) application for Whitewash Waiver; and (3) proposed amendments to the articles of associationNov 3
All Wuhan YZY Biopharma news releases↗

Follow Wuhan YZY Biopharma into a list and get an email when it puts out news.

Follow Wuhan YZY Biopharma
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer